Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of August 2017. The registrant is a foreign private issuer based in Ness Ziona, Israel, reporting pursuant to Rule 13a-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed relates to a grant award:
- Grant Funding: Up to 40% of a NIS 2.7 million budget (approximately NIS 1.08 million) awarded by the Israel Innovation Authority.
- Project: Funding is designated for the ongoing development of the M-001 candidate.
Material Changes
The primary material event reported is the receipt of additional grant funding announced on August 14, 2017. No other material changes to operations or financial status are detailed in this specific filing.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the grant. The filing does not contain updated financial guidance, specific risk factors, contingencies, or unusual items beyond the standard regulatory disclosures.
Investor Verification Checklist
- Verify the exact disbursement schedule and conditions attached to the NIS 2.7 million grant from the Israel Innovation Authority.
- Confirm the current development stage and timeline for the M-001 candidate.
- Review the attached Exhibit 99.1 (Press Release) for further details on the grant terms.
- Note that this filing does not contain audited financial data; refer to the most recent Form 20-F for full financial statements.